References - Homocysteine in Protein Structure/Function and Human Disease - page 150

380. Bogdanski P, Pupek-Musialik D, Dytfeld J, Lacinski M, Jablecka A, Jakubowski H. Plasma
homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients.
Biomed Pharmacother. 2008;62(6):360-5.
381. Durga J, van Tits LJ, Schouten EG, Kok FJ, Verhoef P. Effect of lowering of homocysteine
levels on inflammatory markers: a randomized controlled trial. Arch Intern Med. 2005;165
(12):1388-94.
382. Folsom AR, Desvarieux M, Nieto FJ, Boland LL, Ballantyne CM, Chambless LE. B vitamin
status and inflammatory markers. Atherosclerosis. 2003;169(1):169-74.
383. Ravaglia G, Forti P, Maioli F, Servadei L, Martelli M, Arnone G, et al. Plasma homocysteine
and inflammation in elderly patients with cardiovascular disease and dementia. Exp Gerontol.
2004;39(3):443-50.
384. Peeters AC, van Aken BE, Blom HJ, Reitsma PH, den Heijer M. The effect of homocysteine
reduction by B-vitamin supplementation on inflammatory markers. Clin Chem Lab Med.
2007;45(1):54-8.
385. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B(6) is
associated with elevation of the inflammation marker C-reactive protein independently of
plasma homocysteine levels. Circulation. 2001;103(23):2788-91.
386. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk
factors in apparently healthy men. Am J Cardiol. 1999;84(9):1018-22.
387. Holven KB, Aukrust P, Retterstol K, Hagve TA, Morkrid L, Ose L, et al. Increased levels of
C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab
Invest. 2006;66(1):45-54.
388. Aso Y, Yoshida N, Okumura K, Wakabayashi S, Matsutomo R, Takebayashi K, et al.
Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomo-
cysteinemia. Clin Chim Acta. 2004;348(1-2):139-45.
389. Shai I, Stampfer MJ, Ma J, Manson JE, Hankinson SE, Cannuscio C, et al. Homocysteine as a
risk factor for coronary heart diseases and its association with inflammatory biomarkers,
lipids and dietary factors. Atherosclerosis. 2004;177(2):375-81.
390. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate
hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Transm.
2002;109(12):1445-52.
391. Powers RW, Majors AK, Cerula SL, Huber HA, Schmidt BP, Roberts JM. Changes in
markers of vascular injury in response to transient hyperhomocysteinemia. Metabolism.
2003;52(4):501-7.
392. Holven KB, Scholz H, Halvorsen B, Aukrust P, Ose L, Nenseter MS. Hyperhomocysteinemic
subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear
cells. J Nutr. 2003;133(11):3588-91.
393. Wang G, Woo CW, Sung FL, Siow YL, O K. Increased monocyte adhesion to aortic
endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules.
Arterioscler Thromb Vasc Biol. 2002; 22(11):1777-83.
394. Zhang R, Ma J, Xia M, Zhu H, Ling W. Mild hyperhomocysteinemia induced by feeding rats
diets rich in methionine or deficient in folate promotes early atherosclerotic inflammatory
processes. J Nutr. 2004;134(4):825-30.
395. Lee H, Kim JM, Kim HJ, Lee I, Chang N. Folic acid supplementation can reduce the
endothelial damage in rat brain microvasculature due to hyperhomocysteinemia. J Nutr.
2005;135(3):544-8.
396. Keating AK, Freehauf C, Jiang H, Brodsky GL, Stabler SP, Allen RH, et al. Constitutive
induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase
deficient homocystinuria. Mol Genet Metab. 2011;103(4):330-7.
397. Robert K, Nehme J, Bourdon E, Pivert G, Friguet B, Delcayre C, et al. Cystathionine beta
synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver. Gastroen-
terology. 2005;128(5):1405-15.